SlideShare a Scribd company logo
Fluid Management
Jeffrey Groom, PhD, CRNA
Director and Clinical Associate Professor
Nurse Anesthetist Program
Florida International University
Goal of perioperative fluid management
The goal of perioperative fluid management is to
provide the appropriate amount of parenteral
fluid to maintain adequate:
– intravascular fluid volume,
– left ventricular filling pressure,
– cardiac output,
– systemic blood pressure,
– and ultimately, oxygen delivery to tissues.
Rational approach to fluid management
In addition to surgical considerations
(blood loss, evaporative loss, third spacing),
certain conditions and changes that occur during
the perioperative period can make the
management of fluid balance a challenge,
including preoperative:
• fluid volume status,
• preexisting disease states,
• and the effect of anesthetic drugs on normal
physiology
Management of fluid therapy
• Management of fluid therapy may influence
intraoperative and postoperative morbidity and
mortality.
• Providing sufficient intravascular fluid volume is
essential for adequate perfusion of vital organs.
• Although quantitative considerations are of primary
concern, oxygen carrying capacity, coagulation,
and electrolyte and acid-base balance are also of
critical importance.
Preoperative assessment of
intravascular fluid volume
Preoperative assessment of intravascular fluid volume is
important before induction of anesthesia.
• Common causes of preoperative hypovolemia:
– Bowel preparations, vomiting, diarrhea, diaphoresis,
hemorrhage, burns, and inadequate intake
• Redistribution of intravascular fluid volume without evidence of
external loss is another important cause of preoperative
volume depletion.
– Examples: patients with sepsis, adult respiratory distress
syndrome, ascites, pleural effusions, and bowel
abnormalities.
• Often, these processes are accompanied by increased
capillary permeability resulting in loss of intravascular fluid
volume to interstitial and other fluid compartments.
Evaluation of intravascular fluid volume
• Evaluation of intravascular fluid volume relies on
indirect measurements such as systemic blood
pressure, heart rate, and urine output because
measurements of fluid compartments are not readily
available.
• Even with sophisticated monitoring techniques
(pulmonary artery catheters, arterial oxygen
saturation), the adequacy of intravascular fluid volume
replacement and tissue oxygen delivery to individual
vital organs cannot be precisely determined.
• For these reasons, clinical evaluation of intravascular
fluid volume is necessary.
Clinical Estimation of
Intravascular Fluid Volume
INTRAVASCULAR FLUID VOLUME STATUS
AND ANESTHETIC TECHNIQUE
• Induction of anesthesia with thiopental leads to a
decrease in venous return.
• Induction of anesthesia with propofol produces a
decrease in systemic vascular resistance, cardiac
contractility, and preload.
• Ketamine produces increases in systemic blood
pressure, heart rate, and cardiac output through
stimulation of the sympathetic nervous system and
inhibition of norepinephrine reuptake.
– Direct myocardial depressant effects of ketamine may be
unmasked by exhaustion of catecholamine stores
(congestive heart failure, end-stage shock) and result in
paradoxical decreases in blood pressure when ketamine is
administered
• Neuromuscular blocking drugs, though generally
devoid of direct cardiovascular effects, can lead to
histamine release (Sux, Atracurium) and decreased
systemic vascular resistance or produce venous
pooling because of loss of muscle tone.
• Isoflurane, desflurane, and sevoflurane all decrease
systemic vascular resistance and mildly depress
myocardial contractility. In addition, institution of
positive-pressure ventilation of the patient’s lungs
reduces preload and is particularly likely to decrease
systemic blood pressure in hypovolemic patients.
INTRAVASCULAR FLUID VOLUME STATUS
AND ANESTHETIC TECHNIQUE
• Regional Anesthesia (Spinal & Epidural)
AKA Neuraxial blockade - block sympathetic
nervous system fibers innervating arterial and
venous vascular smooth muscle, causes
vasodilatation, pooling of blood, and decreased
venous return to the heart.
• May cause significant changes in systemic blood
pressure, especially in intravascularly depleted
patients.
• These effects are often mitigated by fluid
administration before the institution of regional
anesthesia.
INTRAVASCULAR FLUID VOLUME STATUS
AND ANESTHETIC TECHNIQUE
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
1. Replacement of preexisting fluid deficits,
2. Replacement of normal losses
(maintenance requirements)
3. Replacement of surgical wound (“third-
space”) losses
4. Replacement of surgical wound
(bleeding) losses
PERIOPERATIVE FLUID THERAPY:
QUALITATIVE CONSIDERATIONS
Crystalloid solutions – NS, LR, Plasma-lyte, Dextrose solutions
• NS - large volumes can lead to a hyperchloremic-induced non-gap
metabolic acidosis
• LR - large volumes can lead to an increased bicarbonate production
from the metabolism of lactate and induce metabolic alkalosis
• LR and Plasma-Lyte contain potassium and should be used with
caution in hyperkalemic patients.
• Calcium in LR prohibits its use in the presence of citrated blood
products.
• Dextrose-containing solutions should be avoided because
hyperglycemic-induced hyperosmolality, osmotic diuresis, and
cerebral acidosis are known complications.
• Infusions of total parenteral nutrition solutions should be continued
during anesthesia and surgery to prevent hypoglycemia; or
alternatively administer dextrose-containing infusion. In either case,
monitor intra op blood glucose.
PERIOPERATIVE FLUID THERAPY:
QUALITATIVE CONSIDERATIONS
• Colloid solutions – albumin, hydroxyethyl starch, and dextran
• Albumin (5% or 25%) is purified from human plasma
– there is no known risk of transmission of hepatitis B or C or HIV.
– However, because albumin is a blood product, Jehovah’s Witness patients
may object to its use for religious reasons.
– The half-life of albumin in plasma is approximately 16 hours, with about 90%
of the dose remaining in the intravascular space 2 hours.
• Hydroxyethyl starch (hetastarch) is a semisynthetic colloid synthesized from
amylopectin
– 6% high-molecular-weight hetastarch in saline (Hespan)
– 6% high-molecular-weight hetastarch in balanced electrolytes (Hextend)
– The half-life for 90% of hydroxyethyl starch particles is 17 days.
• Dextran is a semisynthetic colloid biosynthesized from sucrose
– Based on differing molecular weights, dextran 70 is generally preferred for
volume expansion, whereas dextran 40 is thought to improve blood flow in
the microcirculation, presumably by decreasing blood viscosity.
• Hypersensitivity reactions, including anaphylaxis, have been reported with
albumin, hydroxyethyl starch, and dextran.
• Considerably more expensive than crystalloids.
PERIOPERATIVE FLUID THERAPY:
QUALITATIVE CONSIDERATIONS
COAGULATION ABNORMALITIES
• Bleeding associated with the use of the synthetic colloids has been widely
reported.
• Dextran 70 and, to a lesser extent, dextran 40 produce a dose-related
reduction in platelet aggregation and adhesiveness.
• Hydroxyethyl starch can lead to a reduction in factor VIII and von Willebrand
factor, impairment of platelet function, and prolongation of the partial
thromboplastin time.
• Coagulation studies and bleeding times are not generally significantly
affected after infusions of up to 1 L.
• However, these colloids are best avoided in patients with a known
coagulopathy.
Colloid versus Crystalloid Solutions
• Numerous comparison studies with NO distinct advantages
• Because colloids are more expensive and do not have the same safety
profile as crystalloids, it is hard to justify their use outside situations in which
rapid intravascular fluid volume expansion is needed.
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
1. Replacement of preexisting fluid deficits,
2. Replacement of normal losses
(maintenance requirements)
3. Replacement of surgical wound (“third-
space”) losses
4. Replacement of surgical wound
(bleeding) losses
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
1. Replacement of preexisting fluid deficits
Examples: _____ ml/hr minimum maintenance req
60 kg = ______ 100 kg = _____ 200 kg = _____
Sometimes called
the “4-2-1 Rule”
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
1. Replacement of preexisting fluid deficits
Sometimes called
the “4-2-1 Rule”
Quick Version for patients over 20kg is to take weight (kg) plus 40 (ml/hr)
Hourly Maintenance Fluid Rate ___kg + 40ml = ____ ml/hr
Ex 120 kg pt 120kg + 40 = 160 ml/hr
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy based on:
• The predicted daily maintenance fluid
requirements for healthy adults may exceed
2500ml/day including 20 mEq/L Sodium and
15-20mEq/L Potassium
• Insensible loss (diaphoresis, respiration, etc.)
may exceed 1000ml/day
• Urinary losses to maintain renal function average
1000ml/day, GI losses 200ml/day
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
1. Replacement of preexisting fluid deficits
Hourly Maintenance Fluid Requirement
X Hours NPO
Fluid Deficit
Examples: _____ ml Estimated Fluid Deficit
60kg/8hr = ___ 100kg/10hr = ___ 200kg/12hr= ___
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
1. Replacement of preexisting fluid deficits
usually over 3 hours
1stHR ½ 2nd HR ¼ 3rd HR ¼
Examples: _____ ml Estimated Fluid Deficit
1000 ml deficit = ___ ml 1st HR
___ ml 2nd HR
___ ml 3rd HR
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
1. Replacement of preexisting fluid deficits
Abnormal fluid losses (vomiting, diarrhea, preoperative
bleeding), occult losses (ascites, infected tissues), and
insensible losses (fever, sweating, hyperventilation) must
not be overlooked in the preoperative correction of fluid
deficits so that the hypotension and hypoperfusion that
can occur during induction of anesthesia can be minimized.
(Clinical estimation - No formula for replacement amount)
The fluid used for replacement should be similar in
composition to the fluid lost (Crystalloids).
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
2. Replacement of normal losses
(maintenance requirements)
_____ ml/hr minimum maintenance requirements
(Administered With or Without Surgery Losses)
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
3. Replacement of surgical wound
(“third-space”) losses
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
4. Replacement of surgical wound
(bleeding) losses
Replace 1 mL of blood loss with 3 mL crystalloid solution
Examples:
100ml blood = ___ml cryst
500ml blood = ___ml cryst
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
Perioperative fluid therapy includes:
4. Replacement of surgical wound
(bleeding) losses
Replace 1 mL of blood loss with 3 mL crystalloid solution
4x4 = 10 ml blood
Lap = 100-150 ml
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
• Continually record ongoing estimates of surgical blood loss.
• Include: Measurement of blood in the surgical suction container;
• Estimate: occult bleeding into the wound or under surgical drapes
• Estimate: blood on surgical sponges and laparotomy pads (“laps”)
• Use of irrigating solutions may also complicate the estimates.
• Serial hematocrit values reflect the ratio of blood cells to plasma, not
blood loss.
• Typically, surgeons and anesthesia providers underestimate actual
blood loss.
• Clinical signs such as tachycardia are insensitive and nonspecific.
• Decreasing urine output, decline in arterial pH, and a rising base deficit
may be manifested only when tissue hypoperfusion has become
moderate to severe.
• Therefore, visual estimation of continual blood loss is mandatory to guide
fluid therapy and transfusion.
Replace blood loss with isotonic crystalloid solution at 3ml : 1ml blood loss ratio,
-OR-
milliliter-per-milliliter replacement with colloid or blood
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
PERIOPERATIVE FLUID THERAPY:
QUANTITATIVE CONSIDERATIONS
*
*
Hourly Maintenance Fluid Rate (4-2-1 Rule ml/hr)
60 kg man with 10 hour NPO
having Hemicolectomy 1st Hr 2nd Hr 3rd Hr 4th Hr
Insensible loss 120ml 120ml 120ml 120ml
Deficit 500ml 250ml 250ml -------
Replacement 6ml/kg/hr
When surg starts
360ml 360ml 360ml
Total Hour 620ml 730ml 730ml 480ml
Running Total 620ml 1350ml 2080ml 2560ml
PERIOPERATIVE FLUID THERAPY:
EXAMPLE 1 (insensible Loss Rate)
60 kg man with 10 hour NPO
having Hemicolectomy 1st Hr 2nd Hr 3rd Hr 4th Hr
Maintenance 100ml 100ml 100ml 100ml
Deficit 500ml 250ml 250ml -------
Replacement 8ml/kg/hr
When surg starts
480ml 480ml 480ml
Total Hour 600ml 830ml 830ml 580ml
Running Total 600ml 1430ml 2260ml 2840ml
PERIOPERATIVE FLUID THERAPY:
EXAMPLE 2 (Maintenance Rate)
60 kg man with 10 hour NPO
having Hemicolectomy 1st Hr 2nd Hr 3rd Hr 4th Hr
Insensible loss 120ml 120ml 120ml 120ml
Deficit 500ml 250ml 250ml -------
Replacement
Blood loss
6ml/kg/hr 360ml +
300ml
360ml 360ml
Total Hour 620ml 1030ml 730ml 480ml
Running Total 620ml 1650ml 2380ml 2860ml
PERIOPERATIVE FLUID THERAPY:
EXAMPLE 1 (insensible Loss Rate)
__ kg man with __ hour NPO
having _____-ectomy 1st Hr 2nd Hr 3rd Hr 4th Hr
Insensible loss
(2ml/kg/hr)
Deficit
(adjust prn)
Replacement
(use lower end)
Bleeding
(3:1 Cryst:blood)
Total Hour
Running Total
PERIOPERATIVE FLUID THERAPY:
EXAM (insensible Loss Rate)
Transfusion Considerations
• Considered on a case by case basis
• Blood loss should be replaced with crystalloid or colloid solutions to
maintain intravascular fluid volume until the danger of anemia or
depletion of coagulation factors necessitates the administration of
blood products.
• Below a hemoglobin level of 7 g/dL, resting cardiac output has to
increase greatly to maintain normal oxygen delivery to tissues.
Therefore, blood loss should be replaced with transfusion of
erythrocytes to maintain a hemoglobin concentration between 7 and
8 g/dL. A level of 10 g/dL is generally desired for patients with
significant cardiac or pulmonary disease.
• The most common intraoperative coagulopathy is dilutional
thrombocytopenia, which occurs with either large-volume blood
product transfusion or crystalloid/ colloid administration.
• Factor deficiency is less common in the absence of hepatic
dysfunction because stored blood retains 20% to 30% activity of
factors VII and VIII, which is sufficient for coagulation.
Calculating Allowable Blood Loss
–Estimated Blood Volume (EBV) and ABL
• Blood Volume as a function of total body water
• Composition decreases with age
– Premature 100-120cc/kg
– Newborn 80-90cc/kg
– Infant (age 3-12 months) 75-80cc/kg
– Adult male 70cc/kg
– Adult female 65cc/kg
Hematocrit (70kg male initial crit 45% target 30%)
• If you know what the preoperative HCT is,
• Calculate MABL to a minimum target HCT:
MABL = (EBV) x (Starting HCT – Target HCT)
Starting HCT
MABL = (70cc/kg x 70kg) x (45%-30%)
45%
MABL = (4900) x (15)/45 = 1633ml
Calculating Allowable Blood Loss
Estimate that PT will be at approximate Hct of 30% at a blood loss of 1633 ml
Hematocrit (100kg male initial crit 35% target 25%)
MABL = (EBV) x (Starting HCT – Target HCT)
Starting HCT
MABL = (70cc/kg x 100kg) x (35%-25%)
35%
MABL = (7000) x 10)/35 = 2000ml
Calculating Allowable Blood Loss
Estimate that PT will be at approximate Hct of 25% at a blood loss of 2000 ml
Basics of Anesthesia
Blood Therapy Chapter 24
• Emergency Transfusion – Order of preference
• Type and Screen vs Type and Cross
• Decision to transfuse
• Blood components – PRBCs, Acute Loss,
Complications, FFP
• Transfusion reactions
• Autologous Blood – PreDeposit, Salvage,
Dilution
• Basic nursing procedures to administer blood
products – Safety checks, IV Setup,
Administration, Documentation
CASE - 40 yo 220lb hernia 10hr npo
• Convert pounds to kilograms
• Calculate maintenance
• Calculate deficit
• Calculate 3rd Space replacement
requirement
• Include possible need to replace
blood loss
CASE - 40 yo 220lb hernia 10hr npo
100 kg man with 10 hour
NPO having herniorrhaphy 1st Hr 2nd Hr 3rd Hr 4th Hr
Insensible loss
Deficit
Replacement
Total Hour
Running Total
CASE - 40 yo 220lb hernia 10hr npo
100 kg man with 10 hour
NPO having herniorrhaphy 1st Hr 2nd Hr 3rd Hr 4th Hr
Insensible loss
Deficit
Replacement
Blood loss (200cc)
Blood loss replacement with
IV Crystalloids
100 loss 100 loss
Total Hour
Running
Urine Output
Calculating allowable blood loss
Hematocrit (70kg female initial crit 45% target 30%)
Exam I
• Surgical Services (5% slides/Stoelting Ch3)
• Preanesthesia Assessment (30% slides/text)
• Surgical Patient Positioning (30% slides/text)
• Fluid Management (35% slides/text)

More Related Content

Similar to Intravascular_Fluid_Therapy_anesthesia__b7ca9904.ppt

Perioperative fluid management
Perioperative fluid managementPerioperative fluid management
Perioperative fluid management
Shen-Chih Wang
 
Perioperative fluid therapy logic & evidence
Perioperative fluid therapy logic & evidencePerioperative fluid therapy logic & evidence
Perioperative fluid therapy logic & evidence
padma puppala
 
indra ppt on Hemodialysis in ckd patient
indra ppt on Hemodialysis in ckd patientindra ppt on Hemodialysis in ckd patient
indra ppt on Hemodialysis in ckd patient
IndraYadav16
 

Similar to Intravascular_Fluid_Therapy_anesthesia__b7ca9904.ppt (20)

Iv fluids TYPES OF IV FLIUDS
Iv fluids  TYPES OF IV FLIUDSIv fluids  TYPES OF IV FLIUDS
Iv fluids TYPES OF IV FLIUDS
 
Fluid Management Hooman Rowshan, M.D..pptx
Fluid Management Hooman Rowshan, M.D..pptxFluid Management Hooman Rowshan, M.D..pptx
Fluid Management Hooman Rowshan, M.D..pptx
 
Perioperative fluid management
Perioperative fluid managementPerioperative fluid management
Perioperative fluid management
 
Fluid and electrolytes
Fluid and electrolytes Fluid and electrolytes
Fluid and electrolytes
 
Perioperative fluid therapy logic & evidence
Perioperative fluid therapy logic & evidencePerioperative fluid therapy logic & evidence
Perioperative fluid therapy logic & evidence
 
Fluid and blood therapy 2.12.2020.
Fluid and blood therapy 2.12.2020.Fluid and blood therapy 2.12.2020.
Fluid and blood therapy 2.12.2020.
 
Fluid management in acute pancreatitis
Fluid management in acute pancreatitisFluid management in acute pancreatitis
Fluid management in acute pancreatitis
 
Hipec
HipecHipec
Hipec
 
IV FLUID MANAGEMENT IN SURGICAL PATIENTS.
IV FLUID MANAGEMENT IN SURGICAL PATIENTS.IV FLUID MANAGEMENT IN SURGICAL PATIENTS.
IV FLUID MANAGEMENT IN SURGICAL PATIENTS.
 
Intravenous Fluids In Surgical Patients
Intravenous Fluids In Surgical PatientsIntravenous Fluids In Surgical Patients
Intravenous Fluids In Surgical Patients
 
Seminar on CRRT
Seminar on CRRTSeminar on CRRT
Seminar on CRRT
 
Diueritics_in_CCF_2.pptx
Diueritics_in_CCF_2.pptxDiueritics_in_CCF_2.pptx
Diueritics_in_CCF_2.pptx
 
Laboratory role in renal replacement therapy.pptx
Laboratory role in renal replacement therapy.pptxLaboratory role in renal replacement therapy.pptx
Laboratory role in renal replacement therapy.pptx
 
Periop fluid th ent 7.2021.a
Periop fluid th   ent 7.2021.aPeriop fluid th   ent 7.2021.a
Periop fluid th ent 7.2021.a
 
Fluids and electrolytes.pptx
Fluids and electrolytes.pptxFluids and electrolytes.pptx
Fluids and electrolytes.pptx
 
Fluid management in Neurosurgery
Fluid management in NeurosurgeryFluid management in Neurosurgery
Fluid management in Neurosurgery
 
indra ppt on Hemodialysis in ckd patient
indra ppt on Hemodialysis in ckd patientindra ppt on Hemodialysis in ckd patient
indra ppt on Hemodialysis in ckd patient
 
Crrt minia-final-2018
Crrt minia-final-2018Crrt minia-final-2018
Crrt minia-final-2018
 
Crrt domyat-final
Crrt domyat-finalCrrt domyat-final
Crrt domyat-final
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 

Recently uploaded

Recently uploaded (20)

TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptxANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptxTemporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
 
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
 
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t..."Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
 

Intravascular_Fluid_Therapy_anesthesia__b7ca9904.ppt

  • 1. Fluid Management Jeffrey Groom, PhD, CRNA Director and Clinical Associate Professor Nurse Anesthetist Program Florida International University
  • 2. Goal of perioperative fluid management The goal of perioperative fluid management is to provide the appropriate amount of parenteral fluid to maintain adequate: – intravascular fluid volume, – left ventricular filling pressure, – cardiac output, – systemic blood pressure, – and ultimately, oxygen delivery to tissues.
  • 3. Rational approach to fluid management In addition to surgical considerations (blood loss, evaporative loss, third spacing), certain conditions and changes that occur during the perioperative period can make the management of fluid balance a challenge, including preoperative: • fluid volume status, • preexisting disease states, • and the effect of anesthetic drugs on normal physiology
  • 4. Management of fluid therapy • Management of fluid therapy may influence intraoperative and postoperative morbidity and mortality. • Providing sufficient intravascular fluid volume is essential for adequate perfusion of vital organs. • Although quantitative considerations are of primary concern, oxygen carrying capacity, coagulation, and electrolyte and acid-base balance are also of critical importance.
  • 5. Preoperative assessment of intravascular fluid volume Preoperative assessment of intravascular fluid volume is important before induction of anesthesia. • Common causes of preoperative hypovolemia: – Bowel preparations, vomiting, diarrhea, diaphoresis, hemorrhage, burns, and inadequate intake • Redistribution of intravascular fluid volume without evidence of external loss is another important cause of preoperative volume depletion. – Examples: patients with sepsis, adult respiratory distress syndrome, ascites, pleural effusions, and bowel abnormalities. • Often, these processes are accompanied by increased capillary permeability resulting in loss of intravascular fluid volume to interstitial and other fluid compartments.
  • 6. Evaluation of intravascular fluid volume • Evaluation of intravascular fluid volume relies on indirect measurements such as systemic blood pressure, heart rate, and urine output because measurements of fluid compartments are not readily available. • Even with sophisticated monitoring techniques (pulmonary artery catheters, arterial oxygen saturation), the adequacy of intravascular fluid volume replacement and tissue oxygen delivery to individual vital organs cannot be precisely determined. • For these reasons, clinical evaluation of intravascular fluid volume is necessary.
  • 8. INTRAVASCULAR FLUID VOLUME STATUS AND ANESTHETIC TECHNIQUE • Induction of anesthesia with thiopental leads to a decrease in venous return. • Induction of anesthesia with propofol produces a decrease in systemic vascular resistance, cardiac contractility, and preload. • Ketamine produces increases in systemic blood pressure, heart rate, and cardiac output through stimulation of the sympathetic nervous system and inhibition of norepinephrine reuptake. – Direct myocardial depressant effects of ketamine may be unmasked by exhaustion of catecholamine stores (congestive heart failure, end-stage shock) and result in paradoxical decreases in blood pressure when ketamine is administered
  • 9. • Neuromuscular blocking drugs, though generally devoid of direct cardiovascular effects, can lead to histamine release (Sux, Atracurium) and decreased systemic vascular resistance or produce venous pooling because of loss of muscle tone. • Isoflurane, desflurane, and sevoflurane all decrease systemic vascular resistance and mildly depress myocardial contractility. In addition, institution of positive-pressure ventilation of the patient’s lungs reduces preload and is particularly likely to decrease systemic blood pressure in hypovolemic patients. INTRAVASCULAR FLUID VOLUME STATUS AND ANESTHETIC TECHNIQUE
  • 10. • Regional Anesthesia (Spinal & Epidural) AKA Neuraxial blockade - block sympathetic nervous system fibers innervating arterial and venous vascular smooth muscle, causes vasodilatation, pooling of blood, and decreased venous return to the heart. • May cause significant changes in systemic blood pressure, especially in intravascularly depleted patients. • These effects are often mitigated by fluid administration before the institution of regional anesthesia. INTRAVASCULAR FLUID VOLUME STATUS AND ANESTHETIC TECHNIQUE
  • 11. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 1. Replacement of preexisting fluid deficits, 2. Replacement of normal losses (maintenance requirements) 3. Replacement of surgical wound (“third- space”) losses 4. Replacement of surgical wound (bleeding) losses
  • 12. PERIOPERATIVE FLUID THERAPY: QUALITATIVE CONSIDERATIONS Crystalloid solutions – NS, LR, Plasma-lyte, Dextrose solutions • NS - large volumes can lead to a hyperchloremic-induced non-gap metabolic acidosis • LR - large volumes can lead to an increased bicarbonate production from the metabolism of lactate and induce metabolic alkalosis • LR and Plasma-Lyte contain potassium and should be used with caution in hyperkalemic patients. • Calcium in LR prohibits its use in the presence of citrated blood products. • Dextrose-containing solutions should be avoided because hyperglycemic-induced hyperosmolality, osmotic diuresis, and cerebral acidosis are known complications. • Infusions of total parenteral nutrition solutions should be continued during anesthesia and surgery to prevent hypoglycemia; or alternatively administer dextrose-containing infusion. In either case, monitor intra op blood glucose.
  • 13. PERIOPERATIVE FLUID THERAPY: QUALITATIVE CONSIDERATIONS • Colloid solutions – albumin, hydroxyethyl starch, and dextran • Albumin (5% or 25%) is purified from human plasma – there is no known risk of transmission of hepatitis B or C or HIV. – However, because albumin is a blood product, Jehovah’s Witness patients may object to its use for religious reasons. – The half-life of albumin in plasma is approximately 16 hours, with about 90% of the dose remaining in the intravascular space 2 hours. • Hydroxyethyl starch (hetastarch) is a semisynthetic colloid synthesized from amylopectin – 6% high-molecular-weight hetastarch in saline (Hespan) – 6% high-molecular-weight hetastarch in balanced electrolytes (Hextend) – The half-life for 90% of hydroxyethyl starch particles is 17 days. • Dextran is a semisynthetic colloid biosynthesized from sucrose – Based on differing molecular weights, dextran 70 is generally preferred for volume expansion, whereas dextran 40 is thought to improve blood flow in the microcirculation, presumably by decreasing blood viscosity. • Hypersensitivity reactions, including anaphylaxis, have been reported with albumin, hydroxyethyl starch, and dextran. • Considerably more expensive than crystalloids.
  • 14. PERIOPERATIVE FLUID THERAPY: QUALITATIVE CONSIDERATIONS COAGULATION ABNORMALITIES • Bleeding associated with the use of the synthetic colloids has been widely reported. • Dextran 70 and, to a lesser extent, dextran 40 produce a dose-related reduction in platelet aggregation and adhesiveness. • Hydroxyethyl starch can lead to a reduction in factor VIII and von Willebrand factor, impairment of platelet function, and prolongation of the partial thromboplastin time. • Coagulation studies and bleeding times are not generally significantly affected after infusions of up to 1 L. • However, these colloids are best avoided in patients with a known coagulopathy. Colloid versus Crystalloid Solutions • Numerous comparison studies with NO distinct advantages • Because colloids are more expensive and do not have the same safety profile as crystalloids, it is hard to justify their use outside situations in which rapid intravascular fluid volume expansion is needed.
  • 15. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 1. Replacement of preexisting fluid deficits, 2. Replacement of normal losses (maintenance requirements) 3. Replacement of surgical wound (“third- space”) losses 4. Replacement of surgical wound (bleeding) losses
  • 16. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 1. Replacement of preexisting fluid deficits Examples: _____ ml/hr minimum maintenance req 60 kg = ______ 100 kg = _____ 200 kg = _____ Sometimes called the “4-2-1 Rule”
  • 17. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 1. Replacement of preexisting fluid deficits Sometimes called the “4-2-1 Rule” Quick Version for patients over 20kg is to take weight (kg) plus 40 (ml/hr) Hourly Maintenance Fluid Rate ___kg + 40ml = ____ ml/hr Ex 120 kg pt 120kg + 40 = 160 ml/hr
  • 18. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy based on: • The predicted daily maintenance fluid requirements for healthy adults may exceed 2500ml/day including 20 mEq/L Sodium and 15-20mEq/L Potassium • Insensible loss (diaphoresis, respiration, etc.) may exceed 1000ml/day • Urinary losses to maintain renal function average 1000ml/day, GI losses 200ml/day
  • 19. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 1. Replacement of preexisting fluid deficits Hourly Maintenance Fluid Requirement X Hours NPO Fluid Deficit Examples: _____ ml Estimated Fluid Deficit 60kg/8hr = ___ 100kg/10hr = ___ 200kg/12hr= ___
  • 20. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 1. Replacement of preexisting fluid deficits usually over 3 hours 1stHR ½ 2nd HR ¼ 3rd HR ¼ Examples: _____ ml Estimated Fluid Deficit 1000 ml deficit = ___ ml 1st HR ___ ml 2nd HR ___ ml 3rd HR
  • 21. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 1. Replacement of preexisting fluid deficits Abnormal fluid losses (vomiting, diarrhea, preoperative bleeding), occult losses (ascites, infected tissues), and insensible losses (fever, sweating, hyperventilation) must not be overlooked in the preoperative correction of fluid deficits so that the hypotension and hypoperfusion that can occur during induction of anesthesia can be minimized. (Clinical estimation - No formula for replacement amount) The fluid used for replacement should be similar in composition to the fluid lost (Crystalloids).
  • 22. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 2. Replacement of normal losses (maintenance requirements) _____ ml/hr minimum maintenance requirements (Administered With or Without Surgery Losses)
  • 23. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 3. Replacement of surgical wound (“third-space”) losses
  • 24. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 4. Replacement of surgical wound (bleeding) losses Replace 1 mL of blood loss with 3 mL crystalloid solution Examples: 100ml blood = ___ml cryst 500ml blood = ___ml cryst
  • 25. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS Perioperative fluid therapy includes: 4. Replacement of surgical wound (bleeding) losses Replace 1 mL of blood loss with 3 mL crystalloid solution 4x4 = 10 ml blood Lap = 100-150 ml
  • 26. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS • Continually record ongoing estimates of surgical blood loss. • Include: Measurement of blood in the surgical suction container; • Estimate: occult bleeding into the wound or under surgical drapes • Estimate: blood on surgical sponges and laparotomy pads (“laps”) • Use of irrigating solutions may also complicate the estimates. • Serial hematocrit values reflect the ratio of blood cells to plasma, not blood loss. • Typically, surgeons and anesthesia providers underestimate actual blood loss. • Clinical signs such as tachycardia are insensitive and nonspecific. • Decreasing urine output, decline in arterial pH, and a rising base deficit may be manifested only when tissue hypoperfusion has become moderate to severe. • Therefore, visual estimation of continual blood loss is mandatory to guide fluid therapy and transfusion. Replace blood loss with isotonic crystalloid solution at 3ml : 1ml blood loss ratio, -OR- milliliter-per-milliliter replacement with colloid or blood
  • 28. PERIOPERATIVE FLUID THERAPY: QUANTITATIVE CONSIDERATIONS * * Hourly Maintenance Fluid Rate (4-2-1 Rule ml/hr)
  • 29. 60 kg man with 10 hour NPO having Hemicolectomy 1st Hr 2nd Hr 3rd Hr 4th Hr Insensible loss 120ml 120ml 120ml 120ml Deficit 500ml 250ml 250ml ------- Replacement 6ml/kg/hr When surg starts 360ml 360ml 360ml Total Hour 620ml 730ml 730ml 480ml Running Total 620ml 1350ml 2080ml 2560ml PERIOPERATIVE FLUID THERAPY: EXAMPLE 1 (insensible Loss Rate)
  • 30. 60 kg man with 10 hour NPO having Hemicolectomy 1st Hr 2nd Hr 3rd Hr 4th Hr Maintenance 100ml 100ml 100ml 100ml Deficit 500ml 250ml 250ml ------- Replacement 8ml/kg/hr When surg starts 480ml 480ml 480ml Total Hour 600ml 830ml 830ml 580ml Running Total 600ml 1430ml 2260ml 2840ml PERIOPERATIVE FLUID THERAPY: EXAMPLE 2 (Maintenance Rate)
  • 31. 60 kg man with 10 hour NPO having Hemicolectomy 1st Hr 2nd Hr 3rd Hr 4th Hr Insensible loss 120ml 120ml 120ml 120ml Deficit 500ml 250ml 250ml ------- Replacement Blood loss 6ml/kg/hr 360ml + 300ml 360ml 360ml Total Hour 620ml 1030ml 730ml 480ml Running Total 620ml 1650ml 2380ml 2860ml PERIOPERATIVE FLUID THERAPY: EXAMPLE 1 (insensible Loss Rate)
  • 32. __ kg man with __ hour NPO having _____-ectomy 1st Hr 2nd Hr 3rd Hr 4th Hr Insensible loss (2ml/kg/hr) Deficit (adjust prn) Replacement (use lower end) Bleeding (3:1 Cryst:blood) Total Hour Running Total PERIOPERATIVE FLUID THERAPY: EXAM (insensible Loss Rate)
  • 33. Transfusion Considerations • Considered on a case by case basis • Blood loss should be replaced with crystalloid or colloid solutions to maintain intravascular fluid volume until the danger of anemia or depletion of coagulation factors necessitates the administration of blood products. • Below a hemoglobin level of 7 g/dL, resting cardiac output has to increase greatly to maintain normal oxygen delivery to tissues. Therefore, blood loss should be replaced with transfusion of erythrocytes to maintain a hemoglobin concentration between 7 and 8 g/dL. A level of 10 g/dL is generally desired for patients with significant cardiac or pulmonary disease. • The most common intraoperative coagulopathy is dilutional thrombocytopenia, which occurs with either large-volume blood product transfusion or crystalloid/ colloid administration. • Factor deficiency is less common in the absence of hepatic dysfunction because stored blood retains 20% to 30% activity of factors VII and VIII, which is sufficient for coagulation.
  • 34. Calculating Allowable Blood Loss –Estimated Blood Volume (EBV) and ABL • Blood Volume as a function of total body water • Composition decreases with age – Premature 100-120cc/kg – Newborn 80-90cc/kg – Infant (age 3-12 months) 75-80cc/kg – Adult male 70cc/kg – Adult female 65cc/kg
  • 35. Hematocrit (70kg male initial crit 45% target 30%) • If you know what the preoperative HCT is, • Calculate MABL to a minimum target HCT: MABL = (EBV) x (Starting HCT – Target HCT) Starting HCT MABL = (70cc/kg x 70kg) x (45%-30%) 45% MABL = (4900) x (15)/45 = 1633ml Calculating Allowable Blood Loss Estimate that PT will be at approximate Hct of 30% at a blood loss of 1633 ml
  • 36. Hematocrit (100kg male initial crit 35% target 25%) MABL = (EBV) x (Starting HCT – Target HCT) Starting HCT MABL = (70cc/kg x 100kg) x (35%-25%) 35% MABL = (7000) x 10)/35 = 2000ml Calculating Allowable Blood Loss Estimate that PT will be at approximate Hct of 25% at a blood loss of 2000 ml
  • 37. Basics of Anesthesia Blood Therapy Chapter 24 • Emergency Transfusion – Order of preference • Type and Screen vs Type and Cross • Decision to transfuse • Blood components – PRBCs, Acute Loss, Complications, FFP • Transfusion reactions • Autologous Blood – PreDeposit, Salvage, Dilution • Basic nursing procedures to administer blood products – Safety checks, IV Setup, Administration, Documentation
  • 38. CASE - 40 yo 220lb hernia 10hr npo • Convert pounds to kilograms • Calculate maintenance • Calculate deficit • Calculate 3rd Space replacement requirement • Include possible need to replace blood loss
  • 39. CASE - 40 yo 220lb hernia 10hr npo 100 kg man with 10 hour NPO having herniorrhaphy 1st Hr 2nd Hr 3rd Hr 4th Hr Insensible loss Deficit Replacement Total Hour Running Total
  • 40. CASE - 40 yo 220lb hernia 10hr npo 100 kg man with 10 hour NPO having herniorrhaphy 1st Hr 2nd Hr 3rd Hr 4th Hr Insensible loss Deficit Replacement Blood loss (200cc) Blood loss replacement with IV Crystalloids 100 loss 100 loss Total Hour Running Urine Output
  • 41. Calculating allowable blood loss Hematocrit (70kg female initial crit 45% target 30%)
  • 42. Exam I • Surgical Services (5% slides/Stoelting Ch3) • Preanesthesia Assessment (30% slides/text) • Surgical Patient Positioning (30% slides/text) • Fluid Management (35% slides/text)